Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings

Type I interferon inducers may potentially be engineered to function as antiviral and anticancer agents, or alternatively, vaccine adjuvants, all of which may have clinical applications. We recently described a simple strategy to convert a Toll-like receptor 9 (TLR9) agonist devoid of interferon α (...

Descripción completa

Detalles Bibliográficos
Autores principales: Gungor, Bilgi, Yagci, Fuat Cem, Gursel, Ihsan, Gursel, Mayda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292235/
https://www.ncbi.nlm.nih.gov/pubmed/25610738
http://dx.doi.org/10.4161/21624011.2014.950166
_version_ 1782352464656203776
author Gungor, Bilgi
Yagci, Fuat Cem
Gursel, Ihsan
Gursel, Mayda
author_facet Gungor, Bilgi
Yagci, Fuat Cem
Gursel, Ihsan
Gursel, Mayda
author_sort Gungor, Bilgi
collection PubMed
description Type I interferon inducers may potentially be engineered to function as antiviral and anticancer agents, or alternatively, vaccine adjuvants, all of which may have clinical applications. We recently described a simple strategy to convert a Toll-like receptor 9 (TLR9) agonist devoid of interferon α (IFNα) stimulating activity into a robust Type I interferon inducer with potent vaccine adjuvant activity.
format Online
Article
Text
id pubmed-4292235
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-42922352015-07-03 Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings Gungor, Bilgi Yagci, Fuat Cem Gursel, Ihsan Gursel, Mayda Oncoimmunology Author's View Type I interferon inducers may potentially be engineered to function as antiviral and anticancer agents, or alternatively, vaccine adjuvants, all of which may have clinical applications. We recently described a simple strategy to convert a Toll-like receptor 9 (TLR9) agonist devoid of interferon α (IFNα) stimulating activity into a robust Type I interferon inducer with potent vaccine adjuvant activity. Taylor & Francis 2014-07-03 /pmc/articles/PMC4292235/ /pubmed/25610738 http://dx.doi.org/10.4161/21624011.2014.950166 Text en © 2014 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Gungor, Bilgi
Yagci, Fuat Cem
Gursel, Ihsan
Gursel, Mayda
Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
title Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
title_full Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
title_fullStr Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
title_full_unstemmed Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
title_short Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
title_sort forging a potent vaccine adjuvant: cpg odn/cationic peptide nanorings
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292235/
https://www.ncbi.nlm.nih.gov/pubmed/25610738
http://dx.doi.org/10.4161/21624011.2014.950166
work_keys_str_mv AT gungorbilgi forgingapotentvaccineadjuvantcpgodncationicpeptidenanorings
AT yagcifuatcem forgingapotentvaccineadjuvantcpgodncationicpeptidenanorings
AT gurselihsan forgingapotentvaccineadjuvantcpgodncationicpeptidenanorings
AT gurselmayda forgingapotentvaccineadjuvantcpgodncationicpeptidenanorings

Ejemplares similares